Previous 10 | Next 10 |
home / stock / ipsey / ipsey news
– Treatment emergent adverse events Grade 3 or higher were reported by 20 of 32 patients from the 50/60 dose pooled patient analysis; no patient reported Grade 3 or higher fatigue or peripheral neuropathy (primary endpoint) – – Approximately three quarters of patients...
– Ipsen officially opens North American headquarters at One Main Street and recently renovated R&D and Global External Innovation and Partnering facilities at 650 East Kendall Street – – More than 115 employees join together to support nine local non-profit or...
Debiopharm and Ipsen extend and strengthen their ongoing collaboration to ensure patient access to Decapeptyl ® for the treatment of certain urological, gynecological and pediatric conditions Regulatory News: Debiopharm (Debiopharm – www.debiopharm.com ) and Ipse...
The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted Ipsen ( OTCPK:IPSEY ) a licence update for Dysport in the treatment of focal spasticity. More news on: Ipsen S.A., Ipsen S.A., Healthcare stocks news, Read more ...
New authorisation recognises the role of non-medical injectors (NMIs) such as physiotherapists in focal spasticity and advances standards of care SLOUGH, England , June 5, 2019 /PRNewswire/ -- Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the Medicines and Healthcare Products...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced that new data from clinical studies on investigational uses of cancer medicines cabozantinib (Cabometyx ® ), liposomal irinotecan (Onivyde ® ), and lanreotide autogel (Somatuline ® , marketed as Somatuline ...
5 new chemical entities advancing in pipeline 9 significant regulatory submissions planned from 2019 to 2022 2022 financial outlook of Group Net Sales around €3.2 billion 1 and Core Operating margin greater than 32.0% of net sales Regulatory News: Ipsen (Eur...
Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced its sales for the first quarter of 2019. Q1 2019 Group sales growth of 17.0% as reported, or 15.8% 1 at constant exchange rates and consolidation scope driven by:...
Ipsen ( OTCPK:IPSEY ) have closed acquisition of Clementia Pharmaceuticals following approval of Clementia shareholders and the Quebec Superior Court. More news on: Ipsen S.A., Clementia Pharmaceuticals Inc., Ipsen S.A., Healthcare stocks news, Read more ...
Ipsen’s Rare Diseases portfolio significantly enhanced with late-stage drug candidate, palovarotene, for the treatment of rare bone disorders in adult and pediatric patients Transaction reinforces Ipsen’s strong commitment to providing life-altering treatments to patie...
News, Short Squeeze, Breakout and More Instantly...
Ipsen SA ADR Company Name:
IPSEY Stock Symbol:
OTCMKTS Market:
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases Canada NewsWire Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaboration Following development ...
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen PR Newswire A Novel TCR Vβ bifunctional selective T cell activator molecule for solid tumor treatment Marengo to receive an associated milestone payment a...
Turnstone Biologics Corp. (TSBX) is expected to report $-0.73 for Q4 2023 Exro Technologies Inc (EXROF) is expected to report for Q4 2023 Boyd Gaming Corporation (BYD) is expected to report $1.43 for Q4 2023 Onto Innovation Inc. (ONTO) is expected to report $0.99 for Q4 2023 Motor...